false
0001106838
0001106838
2024-08-14
2024-08-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): August 14, 2024
SONNET
BIOTHERAPEUTICS HOLDINGS, INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-35570 |
|
20-2932652 |
(State
or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer
Identification No.) |
100
Overlook Center, Suite 102
Princeton, New Jersey |
|
08540 |
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (609) 375-2227
N/A
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, $0.0001 Par Value |
|
SONN |
|
The
Nasdaq Capital Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
2.02. Results of Operations and Financial Condition.
On
August 14, 2024, Sonnet BioTherapeutics Holdings, Inc. (the “Registrant”) issued a press release regarding its financial
results for the three months ended June 30, 2024. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated
by reference herein.
Forward-Looking
Statements
This
report, including Exhibit 99.1 furnished herewith, contains forward-looking statements within the meaning of the federal securities laws.
Forward-looking statements typically are identified by use of terms such as “may,” “will,” “should,”
“plan,” “expect,” “anticipate,” “estimate” and similar words, and the opposites of such
words, although some forward-looking statements are expressed differently. Forward-looking statements involve known and unknown risks
and uncertainties that exist in the Registrant’s operations and business environment, which may be beyond the Registrant’s
control, and which may cause actual results, performance or achievements to be materially different from future results, performance
or achievements expressed or implied by such forward-looking statements. All statements other than statements of historical fact are
statements that could be forward-looking statements. For example, forward-looking statements include, without limitation: statements
regarding prospects for additional customers; market forecasts; projections of earnings, revenues, synergies, accretion or other financial
information; and plans, strategies and objectives of management for future operations. The risks and uncertainties referred to above
include, but are not limited to, risks detailed from time to time in the Registrant’s filings with the Securities and Exchange
Commission, including its Annual Report on Form 10-K for the year ended September 30, 2023. These risks could cause actual results to
differ materially from those expressed in any forward-looking statements made by, or on behalf of, the Registrant. Forward-looking statements
represent the judgment of management of the Registrant regarding future events. Although the Registrant believes that the expectations
reflected in such forward-looking statements are reasonable at the time that they are made, the Registrant can give no assurance that
such expectations will prove to be correct. Unless otherwise required by applicable law, the Registrant assumes no obligation to update
any forward-looking statements, and expressly disclaims any obligation to do so, whether as a result of new information, future events
or otherwise.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
Sonnet
BioTherapeutics Holdings, Inc. |
|
a
Delaware corporation |
|
(Registrant) |
|
|
Date:
August 14, 2024 |
By: |
/s/
Pankaj Mohan, Ph.D. |
|
Name: |
Pankaj
Mohan, Ph.D. |
|
Title: |
Chief
Executive Officer |
Exhibit
99.1
Sonnet
BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
Ongoing
progress with both clinical trials of lead program, SON-1010, for solid tumors and Platinum-Resistant Ovarian Cancer (PROC)
Partnership
efforts to support initiation of a Phase 2 clinical trial of SON-080 in Diabetic Peripheral Neuropathy (DPN) underway
Granted
composition of matter patent in key territory – the United States – covering SON-1210 and its application in high-value solid
tumor indications with significant unmet need, including pancreatic cancer
Multiple
value-driving milestones expected in 2024 and throughout 2025 as well as pipeline expansion opportunities throughout high-value solid
tumor market
PRINCETON,
NJ / ACCESSWIRE / August 14, 2024 / Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ:
SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today reported financial results for the three and nine
months ended June 30, 2024 and provided a corporate update.
“We
continue to be encouraged with the data generated by our lead program SON-1010. While preliminary, demonstrating evidence of clinical
benefit at 4 months in 35% of evaluable patients in both of our ongoing studies of SON-1010 represents a significant opportunity to help
patients with PROC and address an indication in desperate need of innovative therapies,” commented Pankaj Mohan, Ph.D., Founder
and CEO of Sonnet. “Additionally, we are actively working to identify a partner to help advance our SON-080 program through the
next phases of development and potentially address a significant unmet need in diabetic peripheral neuropathy.”
Recent
Highlights
| ● | Reported
encouraging data from Phase 1b/2a clinical trial of SON-080 in Chemotherapy-Induced Peripheral
Neuropathy (CIPN) that support advancement into Phase 2 study; |
| ● | Announced
the exercise of warrants for $3.4 million in gross proceeds; |
| ● | Announced
the generation and in vitro characterization of two novel drug candidates, SON-1411
(IL18-FHAB-IL12) and SON-1400 (IL18-FHAB), each containing a modified
version of recombinant human interleukin-18 (IL-18); |
| ● | Presented
the SB221 study of SON-1010 (recombinant human Interleukin-12 linked to Sonnet’s fully-human
albumin binding domain or IL12-FHAB) dosed in combination with atezolizumab (Tecentriq®)
in a ‘Trial in Progress’ poster at the ASCO Annual Meeting in June 2024; and |
| ● | Announced
updated clinical data for SON-1010 as monotherapy or combined with atezolizumab, an anti-PD-L1
antibody, along with an increase in the dose-escalation target. |
Patent
Update
| ● | On
June 11, 2024, the U.S. Patent and Trademark Office (USPTO) granted patent No. 12,006,361,
titled, “Albumin Binding Domain Fusion Proteins,” covering composition
of matter for product candidate SON-1210, the Company’s proprietary, bifunctional version
of human Interleukins 12 (IL-12) and 15 (IL-15), configured using Sonnet’s Fully Human
Albumin Binding (FHAB®) platform. The granted patent is a Continuation
of Patent No. 11,028,166 issued in June 2021. |
“We
remain committed to strengthening the intellectual property portfolio for our FHAB enabling technology platform
and are pleased to further expand our patent estate in this key territory for Sonnet with this granted U.S. patent for SON-1210, our
dual-targeting cytokine. We believe that including SON-1210 in our unique platform may create a next generation cancer treatment
that can enhance patients’ own immune systems to fight cancer. We look forward to identifying a development pathway through a
collaboration for the continued advancement of SON-1210 and offering patients with cancer a much needed therapeutic option,”
added Pankaj Mohan, Ph.D., Founder and CEO of Sonnet.
Lead
Clinical Programs Update
SON-1010:
Targeted Immune Activation Cancer Therapy, Turning ‘Cold’ Tumors ‘Hot’ Initially Targeting Solid Tumors and Platinum-Resistant
Ovarian Cancer (PROC)
Phase
1 Trial (SB101 Trial): Solid Tumors (Monotherapy)
This
first-in-human study is primarily designed to evaluate the safety of multiple ascending doses of SON-1010 in cancer patients and is being
conducted at several sites across the United States.
For
more information about the SB101 clinical trial, visit clinicaltrials.gov and reference identifier NCT05352750.
Phase
1b/2a Trial (SB221 Trial): PROC (Combo with Atezolizumab)
The
second trial is a global Phase 1b/2a multicenter, dose-escalation and randomized proof-of-concept study to assess the safety, tolerability,
PK, PD, and efficacy of SON-1010 administered subcutaneously (SC) in combination with atezolizumab given intravenously (IV).
For
more information about the SB221 clinical trial, visit clinicaltrials.gov and reference identifier NCT05756907.
SON-1010
Program Highlights:
| ● | PK
data reveals about 10-fold extended half-life for SON-1010 compared with rhIL-12 and suggests
tumor targeting by the FHAB. |
| ● | Dose-related
IFNγ response. |
| ● | The
SB101 trial and the SB221 trial have collectively enrolled 61 subjects, with 8 of 23 patients
(35%) with cancer suggesting clinical benefit of SON-1010 (Stable Disease at 4 months). |
| ● | Patients
have received up to 25 cycles of SON-1010 as monotherapy and up to 10 cycles of SON-1010
with atezolizumab (Tecentriq®) without dose-limiting toxicity at any dose
level. |
| ● | Toxicity
is minimized in both trials with the use of a ‘desensitizing’ first dose that
takes advantage of the known tachyphylaxis with rhIL-12, which allows higher maintenance
doses and potential improvements in efficacy. |
| ● | Favorable
safety profile. |
SON-1010
Upcoming Milestones
| ● | Phase
1: Solid Tumors (Monotherapy) |
| ○ | 2H
2024: Safety Data |
| ○ | 1H
2025: Topline Efficacy Data |
| ● | Phase
1b/2a: PROC (Combo with Atezolizumab) |
| ○ | 2H
2024: Additional Safety Data |
| ○ | 2H
2025: RP2D & Topline Efficacy Data |
SON-080:
Low dose of rhIL-6 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN)
Phase
1b/2a Trial (SB211 Trial): Chemotherapy Induced Peripheral Neuropathy (CIPN)
The
SB211 study is a double-blind, randomized, controlled trial of SON-080 conducted at two sites in Australia in patients with persistent
CIPN using a new proprietary version of recombinant human Interleukin-6 (rhIL-6) that builds upon previous work with atexakin alfa. The
goal of the Phase 1b portion of the SB211 study was to confirm safety and tolerability before continued development in Phase 2. As previously
announced in March 2024, a data and safety monitoring board reviewed the unblinded safety and tolerability of SON-080 in the first nine
patients and concluded that the symptoms were tolerable in the initial patients and the study could proceed to Phase 2.
Phase
1b Data Highlights:
| ● | SON-080
demonstrated to be well-tolerated at both 20 µg and 60 µg/dose, which was about
10-fold lower than the maximum tolerated dose (MTD) for IL-6 that was established in previous
clinical evaluations. |
| ● | Pain
and quality of life survey results suggest the potential for rapid improvement of peripheral
neuropathy symptoms and post-dosing durability with both doses, compared to placebo controls. |
For
more information about the SB211 study, visit clinicaltrials.gov and reference identifier NCT05435742.
SON-080
Upcoming Milestones
| ● | Seeking
partnership to support initiation of a Phase 2 clinical trial in DPN, a mechanistically synergistic
and larger, high-value indication with unmet medical need. |
Summary
of Financial Results for the Third Quarter 2024
As
of June 30, 2024, Sonnet had $3.6 million cash on hand, which the Company believes is sufficient to fund operations into November 2024.
Research
and development expenses were $1.7 million for the three months ended June 30, 2024, compared to $2.4 million for the three months ended
June 30, 2023. The decrease of $0.7 million was primarily due to cost saving initiatives, as the Company is managing expenses for liquidity
purposes and is tightening its focus on the research and development projects it has assessed to have the greatest near-term potential.
In addition to transitioning product development activities to cost advantaged locations such as India and Australia, the Company has
reduced expenditures on tertiary programs and suspended antiviral development related to SON-1010, as well as programs related to SON-080
and SON-1210 while it seeks potential partnering opportunities.
General
and administrative expenses were $1.8 million for the three months ended June 30, 2024, compared to $1.5 million for the three months
ended June 30, 2023. The increase of $0.3 million related primarily to costs incurred in connection with the May 2024 ChEF Purchase Agreement
entered into with Chardan Capital Markets LLC and an increase in legal and professional expenses and franchise taxes, partially offset
by a decrease in consulting expenses related to licensing.
About
Sonnet BioTherapeutics Holdings, Inc.
Sonnet
BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bifunctional
action. Known as FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment
(scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues. Sonnet’s FHAB
was designed to specifically target tumor and lymphatic tissue, with an improved therapeutic window for optimizing the safety and efficacy
of immune modulating biologic drugs. FHAB is the foundation of a modular, plug-and-play construct for potentiating a range
of large molecule therapeutic classes, including cytokines, peptides, antibodies, and vaccines.
Forward-Looking
Statements
This
press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the
Company’s cash runway, the Company’s product development, clinical and regulatory timelines, market opportunity, competitive
position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements
that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections
about the industry and markets in which we operate and management’s current beliefs and assumptions.
These
statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,”
“intend,” “plan,” “believe,” “estimate,” “potential,” “predict,”
“project,” “should,” “would” and similar expressions and the negatives of those terms. These statements
relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may
cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed
or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities
and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak
only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether
as a result of new information, future events or otherwise.
Investor
Relations Contact:
JTC
Team, LLC
Jenene
Thomas
833-475-8247
SONN@jtcir.com
Sonnet
BioTherapeutics Holdings, Inc.
Consolidated
Balance Sheets
(unaudited)
| |
June 30, 2024 | | |
September 30, 2023 | |
Assets | |
| | | |
| | |
Current assets: | |
| | | |
| | |
Cash | |
$ | 3,554,331 | | |
$ | 2,274,259 | |
Prepaid expenses and other current assets | |
| 1,053,830 | | |
| 1,677,396 | |
Incentive tax receivable | |
| 519,610 | | |
| 786,574 | |
Total current assets | |
| 5,127,771 | | |
| 4,738,229 | |
Property and equipment, net | |
| 23,733 | | |
| 33,366 | |
Operating lease right-of-use asset | |
| 141,813 | | |
| 193,689 | |
Deferred offering costs | |
| 15,000 | | |
| 49,988 | |
Other assets | |
| 488,480 | | |
| 414,206 | |
Total assets | |
$ | 5,796,797 | | |
$ | 5,429,478 | |
Liabilities and stockholders’ equity (deficit) | |
| | | |
| | |
Current liabilities: | |
| | | |
| | |
Accounts payable | |
$ | 1,879,013 | | |
$ | 2,201,999 | |
Accrued expenses and other current liabilities | |
| 1,149,492 | | |
| 3,230,922 | |
Current portion of operating lease liability | |
| 81,349 | | |
| 73,048 | |
Deferred income | |
| — | | |
| 18,626 | |
Total current liabilities | |
| 3,109,854 | | |
| 5,524,595 | |
Operating lease liability, net of current portion | |
| 68,837 | | |
| 130,863 | |
Total liabilities | |
| 3,178,691 | | |
| 5,655,458 | |
Stockholders’ equity (deficit): | |
| | | |
| | |
Common stock, $0.0001 par value: 125,000,000 shares authorized; 5,218,505 and 1,750,426 issued and outstanding at June 30, 2024 and September 30, 2023, respectively | |
| 522 | | |
| 175 | |
Additional paid-in capital | |
| 117,169,976 | | |
| 110,017,598 | |
Accumulated deficit | |
| (114,552,392 | ) | |
| (110,243,753 | ) |
Total stockholders’ equity (deficit) | |
| 2,618,106 | | |
| (225,980 | ) |
Total liabilities and stockholders’ equity (deficit) | |
$ | 5,796,797 | | |
$ | 5,429,478 | |
Sonnet
BioTherapeutics Holdings, Inc.
Consolidated
Statements of Operations
(unaudited)
| |
Three Months Ended June 30, | | |
Nine Months Ended June 30, | |
| |
2024 | | |
2023 | | |
2024 | | |
2023 | |
Collaboration revenue | |
$ | — | | |
$ | 36,850 | | |
$ | 18,626 | | |
$ | 110,550 | |
Operating expenses: | |
| | | |
| | | |
| | | |
| | |
Research and development | |
| 1,727,033 | | |
| 2,409,471 | | |
| 4,538,363 | | |
| 9,972,055 | |
General and administrative | |
| 1,801,632 | | |
| 1,542,689 | | |
| 4,156,360 | | |
| 5,330,967 | |
Total operating expenses | |
| 3,528,665 | | |
| 3,952,160 | | |
| 8,694,723 | | |
| 15,303,022 | |
Loss from operations | |
| (3,528,665 | ) | |
| (3,915,310 | ) | |
| (8,676,097 | ) | |
| (15,192,472 | ) |
Other income | |
| — | | |
| — | | |
| 4,327,946 | | |
| — | |
Foreign exchange gain (loss) | |
| 23,110 | | |
| (31,432 | ) | |
| 39,512 | | |
| 36,517 | |
Net loss | |
$ | (3,505,555 | ) | |
$ | (3,946,742 | ) | |
$ | (4,308,639 | ) | |
$ | (15,155,955 | ) |
| |
| | | |
| | | |
| | | |
| | |
Per share information: | |
| | | |
| | | |
| | | |
| | |
Net loss per share, basic and diluted | |
$ | (0.70 | ) | |
$ | (2.95 | ) | |
$ | (0.96 | ) | |
$ | (18.98 | ) |
Weighted average shares outstanding, basic and diluted | |
| 5,037,508 | | |
| 1,335,872 | | |
| 4,481,803 | | |
| 798,711 | |
v3.24.2.u1
Cover
|
Aug. 14, 2024 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Aug. 14, 2024
|
Entity File Number |
001-35570
|
Entity Registrant Name |
SONNET
BIOTHERAPEUTICS HOLDINGS, INC.
|
Entity Central Index Key |
0001106838
|
Entity Tax Identification Number |
20-2932652
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
100
Overlook Center
|
Entity Address, Address Line Two |
Suite 102
|
Entity Address, City or Town |
Princeton
|
Entity Address, State or Province |
NJ
|
Entity Address, Postal Zip Code |
08540
|
City Area Code |
(609)
|
Local Phone Number |
375-2227
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common
Stock, $0.0001 Par Value
|
Trading Symbol |
SONN
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14a -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Grafico Azioni Sonnet BioTherapeutics (NASDAQ:SONN)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Sonnet BioTherapeutics (NASDAQ:SONN)
Storico
Da Dic 2023 a Dic 2024